Back

Impact of periprocedural pulmonary hypertension on outcomes after TAVR: novel risk stratification from the OCEAN-TAVI Registry

27 August 2022 (16:00 - 16:10)
Organised by:
Congress Presentation Part of: Transcatheter aortic valve implantation: trends, outcomes, and procedural considerations Aortic Valve Intervention ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Mr Junichi Miyamoto

Tokai University School of Medicine, Kanagawa (Japan)

5 More presentations in this session

Presentation thumbnail
Trends in outcomes, complications and readmission rates in patients undergoing transcatheter aortic valve implantation: a nationwide analysis from 2012 to 2019
Doctor A. Goel (Valhalla, US)
Abstract Slides Video
Presentation thumbnail
Hospital procedural volume and clinical outcomes for transcatheter aortic valve replacement - US nationwide readmission database, 2016-2019.
Doctor O. Al-Taweel (Las Vegas, US)
Abstract Slides Video
Presentation thumbnail
Prevalence and prognostic impact of cardiac amyloidosis in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. AMY-TAVI study.
Doctor D. Lopez Otero (Santiago de Compostela, ES)
Abstract Slides Video
Presentation thumbnail
Bioprosthetic valve fracture during valve-in-valve transcatheter aortic valve replacement: multicenter propensity matched analysis
Doctor G. Bonnet (Bordeaux, FR)
Abstract Slides Video
Presentation thumbnail
Comparison of the safety and efficacy of antithrombotic regimens following TAVR in patients without having an indication for chronic oral anticoagulation
Doctor P. Guedeney (Paris, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Transcatheter aortic valve implantation: trends, outcomes, and procedural considerations

The Event

Event poster

ESC Congress 2022

27 August 2022 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of periprocedural pulmonary hypertension on outcomes after mitral valve transcatheter edge-to-edge repair
thumbnail
Congress Presentation
New treatment strategies based on the pathophysiology of Group 2 pulmonary hypertension
thumbnail
Congress Session
Phenotypes and management strategies in pulmonary hypertension

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources